• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Edesa Biotech Inc.

    5/28/25 4:32:55 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    S-8 1 s8_052625.htm FORM S-8

    As filed with the Securities and Exchange Commission on May 28, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    EDESA BIOTECH, INC.
    (Exact name of registrant as specified in its charter)

     

    British Columbia, Canada   N/A
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
         

    100 Spy Court

    Markham, Ontario, Canada

      L3R 5H6
    (Address of principal executive offices)   (Zip Code)

     

    Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

    (Full title of the plan)

     

    Peter Weiler

    Chief Financial Officer

    c/o Edesa Biotech, Inc.

    100 Spy Court

    Markham, Ontario, Canada L3R 5H6

    (Name and address of agent for service)

     

    (289) 800-9600

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Steven M. Skolnick, Esq.

    Michael J. Lerner, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

      

    Large accelerated filer ☐ Smaller reporting company ☒
    Non-accelerated filer ☒ Accelerated filer ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed by Edesa Biotech, Inc., a British Columbia corporation (the “Registrant”), relating to 1,725,000 common shares, no par value per share (the “Common Shares”), issuable under the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (the “Plan”), which Common Shares are in addition to (i) the 164,736 Common Shares registered on the Registrant’s Form S-8 filed on January 28, 2020 (Registration No. 333-236121), (ii) the 213,858 Common Shares registered on the Registrant’s Form S-8 filed on April 23, 2021 (Registration No. 333-255485), (iii) the 197,143 Common Shares registered on the Registrant’s Form S-8 filed on May 24, 2023 (Registration No. 333-272176), and (iv) the 67,000 Common Shares registered on the Registrant’s Form S-8 filed on May 31, 2024 (Registration No. 333-279887) (collectively, the “Prior Registration Statements”).

     

    This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     All share amounts referenced above and otherwise in this Registration Statement give effect to a 1-for-7 reverse split of the Common Shares effected on October 11, 2023.

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents, which previously have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

      · our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 filed with the SEC on December 13, 2024, as amended on December 20, 2024;
         
      · our Quarterly Reports on Form 10-Q for our fiscal quarters ended December 31, 2024 (filed on February 14, 2025) and March 31, 2025 (filed on May 14, 2025);
         
      · our Current Reports on Form 8-K filed with the SEC on October 4, 2024, October 31, 2024, February 13, 2025, April 4, 2025 and May 28, 2025 (other than any portions thereof deemed furnished and not filed); and
         
      · the description of our Common Shares contained in our Registration Statement on Form 8-A filed with the SEC on November 3, 2015, including any amendment or report filed for the purpose of updating such description, including the Description of Securities filed as Exhibit 4.11 to our Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. The Registrant’s file number with the Commission is No. 001-37619.

     

     

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

     

    Exhibit

    Number

          Incorporated by Reference        

    Filed

    Herewith

      Exhibit Description   Form   File Number   Exhibit   Filing Date  
                             
    5.1   Opinion of Fasken Martineau Dumoulin LLP                   X
    10.1   Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan   8-K   001-37619   10.1   10/25/2019    
    10.2   Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan   8-K   001-37619   10.1   4/23/2021    
    10.3   Amendment No. 2 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan   8-K   001-37619   10.1   5/24/2023    
    10.4   Amendment No. 3 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan   8-K   001-37619   10.1   5/30/2024    
    10.5   Amendment No. 4 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan   8-K   001-37619   10.1   5/28/2025    
    23.1   Consent of Fasken Martineau Dumoulin LLP (included in Exhibit 5.1)                   X
    23.2   Consent of Independent Registered Public Accounting Firm                   X
    24.1   Power of Attorney (included on signature page)                   X
    107   Filing Fee Table                   X

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Markham, Province of Ontario, on May 28, 2025.

     

    EDESA BIOTECH, INC.
       
    By: /s/ Pardeep Nijhawan
      Pardeep Nijhawan
      Director, Chief Executive Officer and Corporate Secretary

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Pardeep Nijhawan and Peter J. Weiler, and each of them, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     Signature   Title   Date
             
    /s/ Pardeep Nijhawan   Director, Chief Executive Officer and Corporate Secretary   May 28, 2025
    Pardeep Nijhawan   (Principal Executive Officer)    
             
    /s/ Peter J. Weiler   Chief Financial Officer   May 28, 2025
    Peter J. Weiler   (Principal Financial and Accounting Officer)    
             
    /s/ Joan Chypyha   Director   May 28, 2025
    Joan Chypyha        
             
    /s/ David Liu   Director   May 28, 2025
    David Liu        

     

    /s/ Sean MacDonald

      Director   May 28, 2025
    Sean MacDonald        
             
    /s/ Patrick Marshall   Director   May 28, 2025
    Patrick Marshall        
             
    /s/ Charles Olson   Director   May 28, 2025
    Charles Olson        
             
    /s/ Carlo Sistilli   Chairman of the Board of Directors   May 28, 2025
    Carlo Sistilli        

     

     

     

     

     

    Get the next $EDSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

      SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

      11/1/24 8:50:52 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edesa Biotech Inc.

      SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

      6/3/24 4:10:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

      SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

      1/29/24 4:29:02 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    SEC Filings

    See more
    • SEC Form S-8 filed by Edesa Biotech Inc.

      S-8 - Edesa Biotech, Inc. (0001540159) (Filer)

      5/28/25 4:32:55 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Edesa Biotech, Inc. (0001540159) (Filer)

      5/28/25 4:05:27 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Edesa Biotech Inc.

      SCHEDULE 13G - Edesa Biotech, Inc. (0001540159) (Subject)

      5/15/25 4:46:04 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      3/25/24 7:00:59 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Nijhawan Pardeep was granted 6,392 shares, increasing direct ownership by 4% to 178,923 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/6/25 5:28:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Weiler Peter J.

      3 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/2/25 5:00:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nijhawan Pardeep was granted 5,784 shares, increasing direct ownership by 3% to 172,531 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      4/3/25 5:25:30 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EDSA
    Leadership Updates

    Live Leadership Updates

    See more

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

      TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2025 and provided an update on its business. During the quarter, the company completed a $15 million equity financing from healthcare-focused institutional investors, existing Edesa shareholders and insiders to support the development of the company's vitiligo drug candidate EB06, anti-CXCL10 monoclonal antibody. The company has subsequently initiated outreach to potential investigators and manufacturing-related

      5/14/25 4:15:30 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference's online portal or contact the company directly at [email protected]. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company develop

      4/28/25 4:30:06 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

      TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

      6/27/23 8:15:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Strategy Expert to Board of Directors

      TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

      3/29/22 9:00:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

      12/20/21 6:08:21 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care